Abstract
Background Individuals with a first episode of psychosis (FEP) show rapid weight gain during the first months of treatment, which is associated with reduction in psychiatric and physical health. Although genetics is assumed to be a significant contributor to this weight gain, its exact role is unknown.
Methods Reference GWAS from BMI and SCZ were obtained to evaluate the pleiotropic landscape between both traits using the pleioFDR software. In parallel, we gathered a population-based FEP cohort of 381 individuals and BMI Polygenic risk-scores (PRS) were evaluated on a sample of 224 individuals. Subsequently, the PRSs obtained from both BMI and the variants shared between the two traits were incorporated into risk models that included demographic and clinical variable to predict BMI increase (ΔBMI) on an independent sample of 157 patients.
Results BMI PRS significantly improved the prediction of absolute BMI and ΔBMI during the first 12 months after the onset of psychotic symptoms. This improvement, was mainly explained by shared variants between SCZ and BMI. In contrast, absolute BMI was predicted mainly by non-shared variants.
Conclusions We validated, for the first time, that genetic factors play a key in the determination of both BMI and ΔBMI in FEP. This finding has important clinical implications in identifying individuals who require specific treatment strategies. Improved risk classification may help prevent associated adverse metabolic events, and reduce overtreatment and costs for both individuals and the healthcare system. It also highlights the importance of studying genetic pleiotropy in the context of medically important comorbidities.
Competing Interest Statement
BC-F has received honoraria (advisory board and educational lectures) and travel expenses from Takeda, Menarini, Angelini, Teva, Otsuka, Lundbeck, and Johnson & Johnson. He has also received unrestricted research grants from Lundbeck. JV-B has received honoraria for his participation as a consultant and/or as a speaker at educational events from Janssen-Cilag and Lundbeck. The rest of authors report no biomedical financial interests or potential conflicts of interest.
Funding Statement
This work was supported by the Catalan Agency of Research and Universities (AGAUR, 2017SGR-00444, PI: EV). GM is supported by Instituto de Salud Carlos III (PI18/00514 and PI21/00612). The Santander (PAFIP) cohort was funded by the following grants: Instituto de Salud Carlos III (FIS00/3095, PI020499, PI050427, PI060507), Plan Nacional de Drogas Research (2005-Orden sco/3246/2004), SENY Fundatio Research (2005-0308007), Fundacion Marques de Valdecilla (A/02/07, API07/011) and MINECO/FEDER (SAF2016-76046-R, SAF2013-46292-R). JV-B is supported by funding from Instituto de Investigacion Valdecilla (INT/A21/10, INT/A20/04). AN is supported by funding from AEI-PGC2018-BI00 (FEDER/UE)(MINECO/FEDER, UE), Unidad de Excelencia Maria de Maeztu, funded by the AEI (CEX2018-000792-M), Secretaria Universitats i Recerca and CERCA Programme of the Departament Economia i Coneixement de la Generalitat de Catalunya (GRC 2017 SGR 880).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Clinical Research Ethics Committee of Cantabria approved the research protocol.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵‡ These authors share senior authorship
Data Availability
All data produced in the present study are available upon reasonable request to the authors
